Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
25 lutego 2016 zaktualizowane przez: Hoffmann-La Roche
Evaluation of Concordance Between the Methods Used in INCa Platforms and the Cobas® 4800 BRAF V600 Mutation Test for Detection of BRAF V600 Mutations in Melanoma in Real Life Setting
This non-interventional study will compare the Cobas BRAF V600 mutation assay with in-house methods used in molecular laboratories for the assessment of the BRAF mutation status in melanoma tumor samples.
No patients will be enrolled in this study.
Data will be collected for approximately 6 months.
Przegląd badań
Status
Zakończony
Warunki
Typ studiów
Obserwacyjny
Zapisy (Rzeczywisty)
420
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Boulogne Billancourt, Francja, 92104
-
Colmar, Francja, 68024
-
Lille, Francja, 59037
-
Lyon, Francja, 69437
-
Marseille, Francja, 13015
-
Montpellier, Francja, 34295
-
Nantes, Francja, 44093
-
Paris, Francja, 75010
-
Pessac, Francja, 33604
-
Rouen, Francja, 76031
-
Vandoeuvre Les Nancy, Francja, 54511
-
Villejuif, Francja, 94505
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Metoda próbkowania
Próbka prawdopodobieństwa
Badana populacja
No patients are enrolled in this study.
Use of melanoma tumor samples.
Opis
Inclusion Criteria:
No patients are enrolled. Use of tumor samples only.
- Histologically proven melanoma tumor sample
- Any type of tumor sample: biopsy or surgical specimen of primary tumor or metastasis
- Tumor samples must be fixed and paraffin-embedded.
Exclusion Criteria:
No patients are enrolled. Use of tumor samples only.
- Fixative unknown
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
INCa molecular genetics laboratory "in-house" methods
BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using "in-house" methods
|
|
Cobas 4800 Mutation Test
BRAF V600 mutations were analysed using Cobas 4800 mutation test
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
BRAF Mutation Status According to Cobas 4800 BRAF V600 Mutation Test vs. INCa Laboratories Molecular Genetics Laboratories
Ramy czasowe: Up to 6 months
|
BRAF V600 mutation status was determined by INCa molecular laboratories "in-house" methods and Cobas 4800 BRAF V600 mutation test.
Samples were analysed as V600 mutation, No V600 mutation and Non evaluable.
Additionally, the type of V600 mutation (E, K, R, D, E2, other V600 mutation, not specified) was also evaluated only by INCa molecular laboratory "in-house" method.
|
Up to 6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Tumor Sample Characteristics-Type of Tumor Sample
Ramy czasowe: Up to 6 months
|
The type of tumor sample used for evaluation of BRAF V600 mutation whether it was a biopsy or surgical specimen were reported
|
Up to 6 months
|
|
Tumor Sample Characteristics - Source of Tumor Sample
Ramy czasowe: Up to 6 months
|
The source of tumor sample for BRAF V600 mutation detection whether taken from internal or external pathology laboratory were reported
|
Up to 6 months
|
|
Type of Pathology Laboratory Performing the Fixation or Embedding-Pre-analytical Method
Ramy czasowe: Up to 6 months
|
The external or internal pathology laboratories involved in the process of fixation or embedding of the tumor sample was evaluated.
|
Up to 6 months
|
|
Time From Sampling to Fixation- Pre-analytical Method
Ramy czasowe: Up to 6 months
|
Time taken from the sampling to the fixation of the tumor sample was reported in range of 0-2 hours, 2-6 hours, >6 hours and unknown.
Number of samples falling in each of the class were reported.
|
Up to 6 months
|
|
Type of Fixative Used- Pre-analytical Method
Ramy czasowe: Up to 6 months
|
The different types of fixative Excell, formol, alcohol formol acetic acid and other, used to fix the tumor samples were reported.
|
Up to 6 months
|
|
Fixation Duration by Pre-analytical Method
Ramy czasowe: Up to 6 months
|
Fixation duration is defined as the amount of time required in hours for the fixation of a samples.
The fixation duration was categorized as <6 hours, 6-24 hours and >24 hours and unknown.
Number of samples falling in each category were reported
|
Up to 6 months
|
|
Slice Thickness by Pre-analytical Method
Ramy czasowe: Up to 6 months
|
Slice thickness of all the tumour samples was measured.
The slice thickness was measured in micrometer.
|
Up to 6 months
|
|
Dewaxing by Pre-analytical Method
Ramy czasowe: Up to 6 Months
|
Dewaxing is a method to recover the DNA from samples.
Dewaxing information was collected as "Yes, No or Missing"
|
Up to 6 Months
|
|
Necrosis Percentage Determination by Pre-analytical Method
Ramy czasowe: Up to 6 months
|
The percentage of necrosis defined as the death of one or more cells in the analysed zone was reported.
|
Up to 6 months
|
|
Percentage of Tumor Cells by Pre-analytical Method
Ramy czasowe: Up to 6 months
|
The percentage of tumor cells in the given tumor sample were reported.
|
Up to 6 months
|
|
Tumor Samples With Presence of Melanin by Pre-analytical Method
Ramy czasowe: Up to 6 months
|
The tumor samples with presence of melanin were categorized as Important, Few, Medium and Absent.
|
Up to 6 months
|
|
DNA Extraction - Extraction Method by Pre-analytical Method
Ramy czasowe: Up to 6 months
|
This method assessed DNA from the tumor samples was extracted by Automated method or Manual method.
|
Up to 6 months
|
|
Median DNA Elution Volume by Pre-analytical Method
Ramy czasowe: Up to 6 months
|
Median DNA elution volume microliters [mcl] was reported.
|
Up to 6 months
|
|
Mean DNA Concentration by Pre-analytical Method
Ramy czasowe: Up to 6 months
|
The DNA concentration in the tissue elute was measured in nanogram per microliter (ng/mcL).
|
Up to 6 months
|
|
Amount of DNA by Pre-analytical Method
Ramy czasowe: Up to 6 months
|
The total DNA concentration extracted from the tissue was measured in nanogram (ng).
|
Up to 6 months
|
|
Size of Amplicons Used by "In-house" Analytical Method
Ramy czasowe: Up to 6 months
|
The method described the size of amplicon used.
It was measured in base pairs (bp).
|
Up to 6 months
|
|
Method of Mutation Detection by "In-house" Analytical Method
Ramy czasowe: Up to 6 months
|
Allele-specific PCR, High Resolution Melting (HRM) + Sanger sequencing, Pyrosequencing, Sanger sequencing, Real time PCR, SNaPshot were used for BRAF V600 mutation detection.
|
Up to 6 months
|
|
Number of Samples Punched in In-house Analytical Method
Ramy czasowe: Up to 6 months
|
Total number of samples for whom punch was used in 'in-house analytical' method are reported.
|
Up to 6 months
|
|
Mean Number of Slices Per Sample Used for "In-house"- Analytical Method
Ramy czasowe: Up to 6 months
|
The mean of number of slices per sample when no punch was used are reported.
|
Up to 6 months
|
|
Median Time Between Receipt of Samples and Determination of Result by "In-house" Analytical Method
Ramy czasowe: Up to 6 months
|
This In-house analytical method measured the time between receipt of samples to the result determination.
It measured the time in days.
|
Up to 6 months
|
|
Technician Work Time Between DNA Extraction and Result by "In-house" Analytical Method
Ramy czasowe: Up to 6 months
|
The working time required by the technician from the time of DNA extraction to the time to obtain the results was measured in hours.
|
Up to 6 months
|
|
Mean DNA Concentration as Measured by COBAS 4800 BRAF V600 Mutation Test-Analytical Method
Ramy czasowe: Up to 6 months
|
The DNA concentration as assessed by COBAS 4800 BRAF V600 Mutation assay was reported.
The unit used to measure the DNA concentration was nanogram/microlitre (ng/mcl)
|
Up to 6 months
|
|
Punch Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method
Ramy czasowe: Up to 6 months
|
The punch done during Cobas 4800 BRAF V600 Mutation Test on the sample was described as Yes or No.
|
Up to 6 months
|
|
Number of Slices Used When No Punch Was Used for Cobas 4800 BRAF V600 Mutation Test- Analytical Method
Ramy czasowe: Up to 6 months
|
This describes the Cobas 4800 BRAF V600 Mutation Test, for the mean of number of slices when No punch method, was used.
Of the 420 samples, punch was Yes, for 45 samples and punch was No, for 375 samples.
|
Up to 6 months
|
|
Median Time Between Receipt of Sample and Determination of Result by Cobas 4800 BRAF V600 Mutation Test -Analytical Method
Ramy czasowe: Up to 6 months
|
This analytical method for cobas 4800 BRAF V600 Mutation Test measured the time between receipt of samples to the result determination.
It measured the time in days.
|
Up to 6 months
|
|
Technician Work Time Between DNA Extraction and Result by Cobas 4800 BRAF V600 Mutation Test - Analytical Method
Ramy czasowe: Up to 6 months
|
This cobas 4800 BRAF V600 Mutation Test analytical method measures the working time required by the technician from the time of DNA extraction to the time to obtain the results.
The time duration was measured in hours.
|
Up to 6 months
|
|
Management of Discordance- Method Used to Manage Discordance
Ramy czasowe: Up to 6 months
|
Crossing DNA, DNA from In-House method analysed with cobas, SNaPshot, DNA from cobas analysed with In-House method, external site control test, Sanger sequencing, Kit CE-IVD Therascreen RGQ Qiagen, Kit Therascreen RGQ BRAF + Pyrosequencing by another platform (PF), Pyrosequencing, Mutation detection On Another Block, (primitive tumor [prm.
tmr]), Sequencing And Therascreen kit (Qiagen) were used for management of discordance between "in-house" method and Cobas 4800 mutation test.
|
Up to 6 months
|
|
Management of Discordance-Final Result for BRAF V600 Mutation Detection
Ramy czasowe: Up to 6 months
|
The final results obtained by discordance management of the 28 discordant samples were BRAF V600 mutation, No BRAF V600 mutation and Non-evaluable.
These results were further assessed by the Investigator and interpreted as final result.
|
Up to 6 months
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 grudnia 2012
Zakończenie podstawowe (Rzeczywisty)
1 kwietnia 2013
Ukończenie studiów (Rzeczywisty)
1 kwietnia 2013
Daty rejestracji na studia
Pierwszy przesłany
6 grudnia 2012
Pierwszy przesłany, który spełnia kryteria kontroli jakości
6 grudnia 2012
Pierwszy wysłany (Oszacować)
7 grudnia 2012
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
28 marca 2016
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
25 lutego 2016
Ostatnia weryfikacja
1 listopada 2015
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- ML28471
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Czerniak złośliwy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ZakończonyStopień IV czerniaka skóry AJCC v6 i v7 | Czerniak oka | Stadium IIIC Czerniak skóry AJCC v7 | Czerniak skóry | Czerniak błony śluzowej | Stadium IIIB czerniak skóry AJCC v7 | Stopień IV czerniaka błony naczyniowej oka AJCC v7 | Stopień IIIB Czerniak błony naczyniowej oka AJCC v7 | Stopień IIIC Czerniak błony... i inne warunkiStany Zjednoczone